Summary
MetLife Inc. (MET) filed an 8-K on October 7, 2014, to report on the remarketing of its Series E Senior Component Debentures. The company successfully remarketed approximately $1 billion in aggregate principal amount of these debentures, split into two tranches: Tranche 1 with a 1.903% interest rate and Tranche 2 with a 4.721% interest rate. This event modifies the maturity dates for these debentures, with Tranche 1 now maturing on December 15, 2017, and Tranche 2 on December 15, 2044. These debentures were originally part of common equity units issued in November 2010. This remarketing is a key event for investors holding these specific debentures or related equity units, as it clarifies their future maturity and interest payment structure. The company also settled some Series E Debentures for cash with holders of common equity units who elected that option. The filing includes exhibits such as the forms of security certificates and a legal opinion from Willkie Farr & Gallagher LLP confirming the validity of the remarketed debentures, providing assurance on the transaction's legal standing.
Key Highlights
- 1MetLife successfully remarketed $499,924,000 of 1.903% Series E Senior Component Debentures (Tranche 1).
- 2MetLife successfully remarketed $499,924,000 of 4.721% Series E Senior Component Debentures (Tranche 2).
- 3The stated maturity for Tranche 1 Debentures is now December 15, 2017.
- 4The stated maturity for Tranche 2 Debentures is now December 15, 2044.
- 5The remarketed debentures were originally part of MetLife's common equity units issued in November 2010.
- 6Approximately $152,000 in Series E Debentures were settled in cash for holders of common equity units who elected that option.
- 7The filing includes legal opinion from Willkie Farr & Gallagher LLP confirming the validity of the remarketed debentures.